255 related articles for article (PubMed ID: 26349548)
21. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
Brickley EB; Strauch CB; Wieland-Alter WF; Connor RI; Lin S; Weiner JA; Ackerman ME; Arita M; Oberste MS; Weldon WC; Sáez-Llorens X; Bandyopadhyay AS; Wright PF
J Infect Dis; 2018 Jan; 217(3):371-380. PubMed ID: 29304199
[TBL] [Abstract][Full Text] [Related]
22. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems.
Kirkpatrick BD; Colgate ER; Mychaleckyj JC; Haque R; Dickson DM; Carmolli MP; Nayak U; Taniuchi M; Naylor C; Qadri F; Ma JZ; Alam M; Walsh MC; Diehl SA; ; Petri WA
Am J Trop Med Hyg; 2015 Apr; 92(4):744-51. PubMed ID: 25711607
[TBL] [Abstract][Full Text] [Related]
23. Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group.
Rennels MB; Ward RL; Mack ME; Zito ET
J Infect Dis; 1996 Feb; 173(2):306-13. PubMed ID: 8568290
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schödel F; Steele AD; Neuzil KM; Ciarlet M
Lancet; 2010 Aug; 376(9741):615-23. PubMed ID: 20692031
[TBL] [Abstract][Full Text] [Related]
25. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.
Dang DA; Nguyen VT; Vu DT; Nguyen TH; Nguyen DM; Yuhuan W; Baoming J; Nguyen DH; Le TL;
Vaccine; 2012 Apr; 30 Suppl 1():A114-21. PubMed ID: 22520120
[TBL] [Abstract][Full Text] [Related]
26. Impact of enterovirus and other enteric pathogens on oral polio and rotavirus vaccine performance in Bangladeshi infants.
Taniuchi M; Platts-Mills JA; Begum S; Uddin MJ; Sobuz SU; Liu J; Kirkpatrick BD; Colgate ER; Carmolli MP; Dickson DM; Nayak U; Haque R; Petri WA; Houpt ER
Vaccine; 2016 Jun; 34(27):3068-3075. PubMed ID: 27154394
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants.
Clements-Mann ML; Dudas R; Hoshino Y; Nehring P; Sperber E; Wagner M; Stephens I; Karron R; Deforest A; Kapikian AZ
Vaccine; 2001 Sep; 19(32):4676-84. PubMed ID: 11535316
[TBL] [Abstract][Full Text] [Related]
28. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age.
Zaman K; Sack DA; Yunus M; Arifeen SE; Podder G; Azim T; Luby S; Breiman RF; Neuzil K; Datta SK; Delem A; Suryakiran PV; Bock HL;
Vaccine; 2009 Feb; 27(9):1333-9. PubMed ID: 19162114
[TBL] [Abstract][Full Text] [Related]
29. Rotavirus Serum IgA Immune Response in Children Receiving Rotarix Coadministered With bOPV or IPV.
Ramani S; Mamani N; Villena R; Bandyopadhyay AS; Gast C; Sato A; Laucirica D; Clemens R; Estes MK; O'Ryan ML
Pediatr Infect Dis J; 2016 Oct; 35(10):1137-9. PubMed ID: 27254033
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of different dosing schedules of the human live attenuate rotavirus vaccine (RV1) in infants and children: a meta-analysis.
Dai X; Bai R; Jian M; Ji Z; Ding Z; Wang F; Bi Y; Manzamaesso A; Chen T; Luo L; Liu A; Bao F
Hum Vaccin Immunother; 2019; 15(6):1228-1236. PubMed ID: 30346870
[TBL] [Abstract][Full Text] [Related]
31. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants.
Ella R; Babji S; Ciarlet M; Blackwelder WC; Vadrevu KM
Vaccine; 2019 Jul; 37(31):4407-4413. PubMed ID: 31178377
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
33. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.
Mir F; Quadri F; Mach O; Ahmed I; Bhatti Z; Khan A; Rehman NU; Durry E; Salama M; Oberste SM; Weldon WC; Sutter RW; Zaidi AK
Lancet Infect Dis; 2015 Aug; 15(8):889-97. PubMed ID: 26093979
[TBL] [Abstract][Full Text] [Related]
34. Trial of a supplemental dose of four poliovirus vaccines.
Sutter RW; Suleiman AJ; Malankar P; Al-Khusaiby S; Mehta F; Clements GB; Pallansch MA; Robertson SE
N Engl J Med; 2000 Sep; 343(11):767-73. PubMed ID: 10984564
[TBL] [Abstract][Full Text] [Related]
35. Head-to-head comparison of the immunogenicity of RotaTeq and Rotarix rotavirus vaccines and factors associated with seroresponse in infants in Bangladesh: a randomised, controlled, open-label, parallel, phase 4 trial.
Velasquez-Portocarrero DE; Wang X; Cortese MM; Snider CJ; Anand A; Costantini VP; Yunus M; Aziz AB; Haque W; Parashar U; Sisay Z; Soeters HM; Hyde TB; Jiang B; Zaman K
Lancet Infect Dis; 2022 Nov; 22(11):1606-1616. PubMed ID: 35961362
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of a three dose and five dose oral human rotavirus vaccine (RIX4414) schedule in south Indian infants.
Kompithra RZ; Paul A; Manoharan D; Babji S; Sarkar R; Mathew LG; Kang G
Vaccine; 2014 Aug; 32 Suppl 1():A129-33. PubMed ID: 25091666
[TBL] [Abstract][Full Text] [Related]
37. A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada.
Dennehy PH;
Vaccine; 2006 May; 24(18):3780-1. PubMed ID: 16111790
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM
Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
[TBL] [Abstract][Full Text] [Related]
40. Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants.
Rongsen-Chandola T; Strand TA; Goyal N; Flem E; Rathore SS; Arya A; Winje BA; Lazarus R; Shanmugasundaram E; Babji S; Sommerfelt H; Vainio K; Kang G; Bhandari N
Vaccine; 2014 Aug; 32 Suppl 1():A134-9. PubMed ID: 25091668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
